Literature DB >> 6490207

The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells.

L Eisenbach, N Hollander, L Greenfeld, H Yakor, S Segal, M Feldman.   

Abstract

Two clones of the 3LL Lewis lung carcinoma, a low-metastatic clone A9 and a high-metastatic clone D122, were studied for MHC expression and immunogenic properties. Using monoclonal antibodies, we demonstrated that the A9 clone expresses both the H-2Kb and the H-2Db, whereas the D122 expresses only the H-2Db, and lacks the expression of the H-2Kb encoded molecules. Cells of the low-metastatic clone A9 grew progressively in syngeneic (C57BL/6J) or in F1 mice, but were rejected in allogeneic recipients. The high-metastatic D122 grew progressively in all mouse strains tested, yet metastases were formed only in syngeneic recipients. When H-2 recombinant mice were used, the A9 again manifested a significantly greater immunogenic potency than the metastatic D122, which grew in all 4 recombinants tested. Metastases, however, were formed in B10HTG and to a lesser extent in B10A(4R), thus indicating that metastasis formation is restricted by both C57BL background and H-2Db sub region. We subsequently tested whether the higher immunogenicity of the H-2Kb-positive A9 cells is expressed also in syngeneic mice, to examine whether this could account for its low metastatic phenotype. We found that immunization by A9 cells significantly inhibited the growth of a subsequent A9 graft and even of D122, yet D122 did not retard the growth of secondary D122 or A9 cells. The increased immunogenic effect was expressed also in the generation of syngeneic cytotoxic lymphocytes by A9 but not by D122 cells. We suggest that expression of H-2K molecules on the 3LL clones, immunogenicity and the metastatic phenotype are causally related in this system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490207     DOI: 10.1002/ijc.2910340421

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

Authors:  D Stepensky; E Tzehoval; E Vadai; L Eisenbach
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma.

Authors:  P L Lollini; C De Giovanni; G Nicoletti; A Bontadini; P L Tazzari; L Landuzzi; K Scotlandi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

Review 3.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Authors:  Mayrel Labrada; Isabel Pablos; Francesca Prete; Giselle Hevia; Marilyn Clavell; Federica Benvenuti; Luis E Fernández
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Graft-specific MHC class II gene expression in response to allogeneic stimulus in heterotopic murine cardiac allografts.

Authors:  R Xu; J F Burdick; A Scott; W E Beschorner; W Adler; D S Kittur
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

6.  Generation of induced pluripotent stem cells from mouse cancer cells.

Authors:  Frances Ka-Yin Lin; Yiu-Loon Chui
Journal:  Cancer Biother Radiopharm       Date:  2012-08-14       Impact factor: 3.099

7.  Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen.

Authors:  A Sacchi; S Kennel; P G Natali; G Tibursi; C A Ghetti
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

8.  Selection for enhanced adhesion to microvessel endothelial cells or resistance to interferon-gamma modulates the metastatic potential of murine RAW117 large-cell lymphoma cells.

Authors:  R A LaBiche; R J Tressler; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1993-11       Impact factor: 5.150

9.  HLA Class I Expressions on Peripheral Blood Mononuclear Cells in Colorectal Cancer Patients.

Authors:  Zhi-Mian Zhang; Xiao Guan; Ying-Jie Li; Ming-Chen Zhu; Xiao-Jing Yang; Xiong Zou
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

10.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.